Efficacy and safety of apatinib mesylate tablets combined with tegafur, gimeracil and oteracil potassium capsules and oxaliplatin in treatment of advanced gastric cancer
Guo Jun
Wang Na
Liu Dengxiang
Sun Yawei
Jin Yi
Zhang Juping
Qiu Peng
Abstract：Objective To investigate the efficacy and safety of apatinib mesylate tablets combined with tegafur, gimeracil and oteracil potassium capsules and oxaliplatin in treatment of advanced gastric cancer. Methods Sixty patients with advanced gastric cancer admitted to Xingtai People's Hospital from July2015 to July 2016 were randomly divided into control group and observation group, with 30 cases in each group. The control group was treated with oxaliplatin mannitol for injection and tegafur, gimeracil and oteracil potassium capsules. The observation group took apatinib mesylate tablets on the basis of control group. Clinical efficacy, adverse reactions and 5-year survival rate were analyzed. Results Remission rate and control rate in the observation group were significantly higher than those in the control group[46. 7％(14/30) vs 13. 3％(4/30), 73. 3％(22/30) vs 33.3％(10/30)] (both P <0. 001). There was no significant difference in the incidence of major adverse reactions between groups(P>0. 05). The 48- and 60-month survival rates in the observation group were signifi-cantly higher than those in the control group [90. 0％(27/30) vs 70. 0％(21/30), 86. 7％(26/30) vs 67. 7％(20/30)](both P<0.05). Conclusion Apatinib mesylate tablets combined with tegafur, gimeracil and oteracil potassium capsules and oxaliplatin are safe and effective in treating advanced gastric cancer.
Keywords：Advanced gastric cancerApatinib mesylate tablets
Publication Date：2020-04-08
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：3( 577-579 )